GSK Oncology Investor & Analyst Update

On Tuesday, 12 December 2017, GSK hosted an investor conference call following the presentation of scientific and clinical data on GSK2857916, GSK's anti-BCMA (B-cell Maturation Antigen) antibody-drug conjugate presented at the 59th American Society of Hematology (ASH) annual meeting.

The call was hosted by Luke Miels, President, GSK Global Pharmaceuticals and Axel Hoos, SVP and Therapy Area Head of Oncology R&D. The call also featured participation from an external expert in multiple myeloma.